Search

The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70 Gy, 60 Gy or 50 Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan–Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57 months and 69.6 months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.

The liver is a common organ of metastases from most solid malignancies, including breast cancer, and breast cancer with liver metastases (BCLM) has a poor prognosis despite advances in systemic therapies. It has become widely recognized that local treatments for oligometastases with curative intent could improve disease control and survival outcomes under certain conditions. Regarding local therapy for BCLM, surgical resection had been the first choice though its indications were quite limited. Recently, an increasing number of prospective trials on stereotactic body radiation therapy (SBRT) for liver metastases (LMs) were published, reporting excellent tumor control with less toxicity. According to these reports, breast cancer origin is a favorable prognostic factor in SBRT for liver metastasis. Further research on patient selection and optimal dose fractionation will establish SBRT as a safe and feasible alternative treatment for resection and ablation in selected patients with BCLM. This review intends to provide evidence on the background and methods of focal radiation therapy for LMs, especially BCLM, and describes the current and future role of SBRT in the treatment of BCLM.